ZFAS1 and hepatocellular carcinoma: Therefore, we hypothesized that, although ZFAS1 itself did not contribute to the sorafenib resistance, its upregulation by sorafenib may act as a predictive prognostic biomarker in HCC patients receiving sorafenib therapy.